Company intelligence / Profile preview
Finch Therapeutics
Somerville, Massachusetts, United Statesfinchtherapeutics.com ↗
- Ownership
- Public · FNCH
- Development stage
- Phase 3
01
Overview
Finch’s lead candidate CP101 showed positive results in a Phase 2 trial for recurrent C. difficile infection with an ~80% sustained cure rate at eight weeks and similar safety to placebo. The PRISM4 Phase 3 trial was initiated but discontinued in early 2023 due to strategic restructuring. Other programs remain preclinical or paused[6][7].
- Therapeutic areas
- GastroenterologyNeurologyInfectious Diseases
- Modalities
- Microbiome therapeutics (oral microbiota-based drugs)Biological drugs (microbial consortia)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceuticals – partnership focused on developing targeted microbiome therapeutics for inflammatory bowel disease[6].
Beyond the preview
Go deeper on Finch Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Finch Therapeutics.